SHN7

SHN7 (72 h) potently inhibits the proliferation of triple-negative breast cancer (TNBC) cells including Hs578T, HCC1937, MDA-MB-231 and MDA-MB-468, with IC₅₀ values ranging from 0.16 μM to 0.97 μM, and exhibits selective cytotoxicity against the healthy mammary epithelial cell line MCF-10A^[1].
SHN7 (0.1-0.3 μM) induces ROS production and DNA damage in Hs578T cells in a dose-dependent manner, both of which are partially mediated by NQO1^[1].
SHN7 (30 min) potently and selectively inhibits HDAC1 (IC₅₀ = 30 nM) and HDAC6 (IC₅₀ = 10 nM)^[1].
SHN7 is a high-performance NQO1 substrate with a catalytic efficiency (k_cat/K_m) of 5.80 × 10⁶ M^-1s^-1[1].
SHN7 (0.31-20.00 μM) binds directly to purified human STAT3 protein, with a dissociation constant (K_D) of 8.9 μM^[1].
SHN7 (0.1-0.3 μM; 72 h) dose-dependently arrests Hs578T cells at the G2/M phase of the cell cycle^[1].
SHN7 (0.1-0.3 μM; 72 h) induces apoptosis in Hs578T cells in a dose-dependent manner, with an apoptosis rate of approximately 60% at the concentration of 0.3 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.